Læknablaðið - 15.12.2011, Qupperneq 33

Y F I R L I T
utanríkisþjónustu ríkis á borð við ísland, hvort sem það hefur
orðið fyrir tímabundnum skakkaföllum eða ekki, sé þróunarsam-
vinna.
Einfaldar forvarnir eins og þær sem framkvæma má með þró-
unaraðstoð krefjast augljóslega ekki sérhæfðrar læknisfræðilegrar
kunnáttu. Þær forvarnaraðgerðir má telja til almennrar baráttu
gegn fátækt í heiminum. Fjöldalyfjagjafir hafa einnig þann kost
að vera einfaldar í framkvæmd, svo sérfræðikunnáttu er ekki þörf
við dreifingu lyfja. Því er það ekki svo að læknar þurfi að vera
staddir á vettvangi til að hafa áhrif á framvindu sjúkdómanna sem
um ræðir. Hins vegar koma gefendur fjármuna til VSÞ úr ýmsum
áttum og hafa ekki alltaf forsendur til að meta í hvers konar verk-
efni fjármagn vantar helst. Læknar, bæði hérlendis og erlendis,
þurfa því að nýta áhrif sín og þekkingu til að leiðbeina gefendum
og vera málsvari smitaðra, svo þessi vanrækti sjúklingahópur fái
viðunandi greiningu, forvarnir og meðferð. íslendingar hafa allar
forsendur til að vera mun virkari á þessum sviðum en nú. Við
höfum mannafla, þekkingu, fjármuni og síðast en ekki síst áhuga.
Fátt væri okkur verðugra en að nýta hann betur.
Heimildir
1. Vanderelst D, Speybroeck N. Quantifying the lack of
scientific interest in neglected tropical diseases. PLoS
neglected tropical diseases 2010;4:e576.
2. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects
of neglected tropical diseases. Lancet 2010; 375: 239-47.
3. WHO. The global burden of disease: 2004 update; 2008.
4. King CH, Bertino AM. Asymmetries of poverty: why
global burden of disease valuations underestimate the
burden of neglected tropical diseases. PLoS neglected
tropical diseases 2008;2:e209.
5. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever
as a public health, social and economic problem in the 21st
century. Trends Microbiol 2002; 10:100-3.
6. Moran M, Guzman J, Ropars AL, et al. Neglected disease
research and development: how much are we really
spending? PLoS Med 2009;6:e30.
7. Neglected tropical diseases. 2009. who.int/neglected_
diseases/faq/en/index5.html. - júlí 2011.
8. Mendoza N, Li A, Gill A, Tyring S. Filariasis: diagnosis and
treatment. Dermatol Ther 2009; 22:475-90.
9. Mathers CD, Ezzati M, Lopez AD. Measuring the burden
of neglected tropical diseases: the global burden of disease
framework. PLoS Negl Trop Dis 2007; l:ell4.
10. Enk CD. Onchocerciasis--river blindness. Clin Dermatol
2006; 24:176-80.
11. Bethony J, Brooker S, Albonico M, et al. Soil-transmitted
helminth infections: ascariasis, trichuriasis, and
hookworm. Lancet 2006; 367:1521-32.
12. Soil-transmitted helminths. 2010. who.int/intestinal_
worms/en/ - júlí 2011.
13. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger
J. Schistosomiasis and water resources development:
systematic review, meta-analysis, and estimates of people
at risk. The Lancet Infect Dis 2006; 6:411-25.
14. Parkin DM. The global health burden of
infection-associated cancers in the year 2002. Int J Cancer
2006; 118:3030-44.
15. Jukes MC, Nokes CA, Alcock KJ, et al. Heavy
schistosomiasis associated with poor short-term memory
and slower reaction times in Tanzanian schoolchildren.
Trop Med Int Health 2002; 7:104-17.
16. Skímisson K, Kolarova L. Sundmannakláði í Landmanna-
laugum. Læknablaðið 2005; 91: 729-36.
17. Wright HR, Tumer A, Taylor HR. Trachoma. Lancet 2008;
371:1945-54.
18. David CV, Craft N. Cutaneous and mucocutaneous
leishmaniasis. Dermatol Ther 2009; 22:491-502.
19. Desjeux P. Leishmaniasis: current situation and new
perspectives. Comp Immunol Microbiol Infect Dis 2004;
27: 305-18.
20. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gúrtler
RE. The Challenges of Chagas Disease - Grim Outlook or
Glimmer of Hope? PLoS Med 2007; 4:1852-7.
21. Webster DP, Farrar J, Rowland-Jones S. Progress towards a
dengue vaccine. Lancet Infect Dis 2009; 9:678-87.
22. Mandeville KL, Krabshuis J, Ladep NG, Mulder CJ,
Quigley EM, Khan SA. Gastroenterology in developing
countries: issues and advances. World J Gastroenterol
2009; 15:2839-54.
23. Stanley SL, Jr. Amoebiasis. Lancet 2003; 361:1025-34.
24. Marcos LA, DuPont HL. Advances in defining etiology
and new therapeutic approaches in acute diarrhea. J Infect
2007; 55:385-93.
25. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin
Dermatol 2009; 27: 291-305.
26. Bamett ED. Yellow fever: epidemiology and prevention.
Clin Infect Dis 2007; 44: 850-6.
27. Brun R, Blum J, Chappuis F, Burri C. Human African
trypanosomiasis. Lancet 2010; 375:148-59.
28. Hopkins DR, Ruiz-Tiben E, Downs P, Withers PC, Jr., Roy
S. Dracunculiasis Eradication: Neglected No Longer. Am J
Trop Med Hyg 2008; 79:474-9.
29. Simarro PP, Jannin J, Cattand P. Eliminating human
African trypanosomiasis: where do we stand and what
comes next? PLoS Med 2008; 5: e55.
30. Metrics: Disability-Adjusted Life Year (DALY). 2010. who.
int/healthinfo/global_burden_disease/metrics_daly/en/
- maí 2010.
31. Hotez PJ, Alibek K. Central Asia's Hidden Burden of
Neglected Tropical Diseases. PLoS Negl Trop Dis 2011; 5:
el224.
32. Burkot TR, Durrheim DN, Melrose WD, Speare R,
Ichimori K. The argument for integrating vector control
with multiple dmg administration campaigns to ensure
elimination of lymphatic filariasis. Filaria J 2006; 5: 10.
33. Wang LD, Chen HG, Guo JG, et al. A strategy to control
transmission of Schistosoma japonicum in China. N Engl J
Med 2009; 360:121-8.
34. CfDCaP. Progress toward global eradication of
dracunculiasis, January 2008-June 2009. Morb Mortal
Wkly Rep 2009; 58:1123-5.
35. Lob-Levyt J, Affolder R, Rizzo I, Burgess C, Bchir A. A
prescription for drug delivery. Nature 2007; 449:170-2.
36. Jauréguiberry S, Paris L, Caumes E. Acute schistosomiasis,
a diagnostic and therapeutic challenge. Clin Microbiol
Infect 2010; 16:225-31.
37. Hopkins AD. Ivermectin and onchocerciasis: is it all
solved? Eye (Lond) 2005; 19:1057-66.
38. Parker M, Allen T. Does mass drug administration for
the integrated treatment of neglected tropical diseases
really work? Assessing evidence for the control of
schistosomiasis and soil-transmitted helminths in Uganda.
Health research policy and systems / BioMed Central
2011; 9: 3.
39. Enserink M. Global health. Some neglected diseases are
more neglected than others. Science 2009; 323: 700.
40. WHO. World Malaria Report 2009; 2009.
41. Butler D. Lost in translation. Nature 2007; 449:158-9.
42. Hopkins AL, Witty MJ, Nwaka S. Mission possible. Nature
2007; 449:166-9.
43. WHO. Leprosy fact sheet. Wkly Epidemiol Rec 2010; 85:
46-8.
44. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global
programme to eliminate lymphatic filariasis: health
impact after 8 years. PLoS Negl Trop Dis 2008; 2: e317.
45. Singer PA, Bemdtson K, Tracy CS, et al. A tough transition.
Nature 2007; 449:1 60-3.
46. Wolfson LJ, Gasse F, Lee-Martin SP, et al. Estimating
the costs of achieving the WHO-UNICEF Global
Immunization Vision and Strategy, 2006-2015. Bull World
Health Organ 2008; 86:27-39.
47. The 0.7% target: An in-depth look. 2006.
unmillenniumproject.org/press/07.htm - júlí 2011.
48. Þjóðhagsreikningar. 2010. hagstofa.is/Hagtolur/Thjod-
hagsreikningar/Thjodhagsreikningar - júlí 2011.
ENGLISH SUMMARY
Neglected tropical diseases - review
Kristjansson J, Gudmundsson S
Neglected tropical diseases include a variety of infectious diseases. This review shortly describes the most common diseases. Those infected usually
live at a low socioeconomic status and rarely have access to satisfactory health care. The neglected diseases are common and have a high burden
of disease. In comparison to HIV, malaria and tuberculosis this group of diseases is in fact neglected. Certain diseases within the group are more
neglected than others. Investment for research does not appear to be decided in proportion to burden of disease. Much can be gained by exterm-
ination of these diseases. The solution is to integrate improvement of living standards and battling diseases. Iceland has a role to play.
Key words: Neglected tropical diseases, DALY, development aid.
Correspondence: Július Kristjánsson, juk2@hi.is
LÆKNAblaðið 2011/97 697